Great to see the growth from the team and de-risking that happened over the year.
Start of 2021:
-1 asset
-1 clinical program
-1 disease area
-Share price: 36 cents
Today:
-7 assets
-8 clinical programs
-10 disease areas
-Share price: 21.5 cents
I think it is a bargain at these prices. Another example of the Aussie market not understanding biotechs, and the typical investor not having the patience for biotechs. DYOR
Chimeric: Media Thread, page-221
-
- There are more pages in this discussion • 667 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CHM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $12.67M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
| CHM (ASX) Chart |
Day chart unavailable